582 related articles for article (PubMed ID: 29129717)
1. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.
Huang HT; Dobrovolsky D; Paulk J; Yang G; Weisberg EL; Doctor ZM; Buckley DL; Cho JH; Ko E; Jang J; Shi K; Choi HG; Griffin JD; Li Y; Treon SP; Fischer ES; Bradner JE; Tan L; Gray NS
Cell Chem Biol; 2018 Jan; 25(1):88-99.e6. PubMed ID: 29129717
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
[TBL] [Abstract][Full Text] [Related]
3. Protein degradation through covalent inhibitor-based PROTACs.
Xue G; Chen J; Liu L; Zhou D; Zuo Y; Fu T; Pan Z
Chem Commun (Camb); 2020 Feb; 56(10):1521-1524. PubMed ID: 31922153
[TBL] [Abstract][Full Text] [Related]
4. PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.
Tinworth CP; Lithgow H; Dittus L; Bassi ZI; Hughes SE; Muelbaier M; Dai H; Smith IED; Kerr WJ; Burley GA; Bantscheff M; Harling JD
ACS Chem Biol; 2019 Mar; 14(3):342-347. PubMed ID: 30807093
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
[TBL] [Abstract][Full Text] [Related]
6. Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes.
Schiemer J; Horst R; Meng Y; Montgomery JI; Xu Y; Feng X; Borzilleri K; Uccello DP; Leverett C; Brown S; Che Y; Brown MF; Hayward MM; Gilbert AM; Noe MC; Calabrese MF
Nat Chem Biol; 2021 Feb; 17(2):152-160. PubMed ID: 33199914
[TBL] [Abstract][Full Text] [Related]
7. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.
Donovan KA; Ferguson FM; Bushman JW; Eleuteri NA; Bhunia D; Ryu S; Tan L; Shi K; Yue H; Liu X; Dobrovolsky D; Jiang B; Wang J; Hao M; You I; Teng M; Liang Y; Hatcher J; Li Z; Manz TD; Groendyke B; Hu W; Nam Y; Sengupta S; Cho H; Shin I; Agius MP; Ghobrial IM; Ma MW; Che J; Buhrlage SJ; Sim T; Gray NS; Fischer ES
Cell; 2020 Dec; 183(6):1714-1731.e10. PubMed ID: 33275901
[TBL] [Abstract][Full Text] [Related]
8. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
[TBL] [Abstract][Full Text] [Related]
9. Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair.
Ye Z; Wang Y; Wu H; Song T; Li X; Liu Q; Wang C
Chembiochem; 2021 Jan; 22(1):129-133. PubMed ID: 32979005
[TBL] [Abstract][Full Text] [Related]
10. A Fast and Clean BTK Inhibitor.
Gabizon R; London N
J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
[TBL] [Abstract][Full Text] [Related]
11. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
12. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
[TBL] [Abstract][Full Text] [Related]
13. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA
Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Sun D; Yang Y; Lyu J; Zhou W; Song W; Zhao Z; Chen Z; Xu Y; Li H
J Med Chem; 2016 Jul; 59(13):6187-200. PubMed ID: 27266526
[TBL] [Abstract][Full Text] [Related]
15. FLT3 Inhibitors in the Management of Acute Myeloid Leukemia.
Zappone E; Defina M; Aprile L; Bartalucci G; Gozzetti A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1028-1032. PubMed ID: 27748173
[TBL] [Abstract][Full Text] [Related]
16. Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit.
Nakano H; Hasegawa T; Imamura R; Saito N; Kojima H; Okabe T; Nagano T
Bioorg Med Chem Lett; 2016 May; 26(9):2370-4. PubMed ID: 26995531
[TBL] [Abstract][Full Text] [Related]
17. Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL.
Lhermitte L; Ben Abdelali R; Villarèse P; Bedjaoui N; Guillemot V; Trinquand A; Libura M; Bedin AS; Petit A; Dombret H; Leverger G; Ifrah N; Hermine O; Macintyre E; Asnafi V
Leukemia; 2013 Feb; 27(2):305-14. PubMed ID: 22751451
[TBL] [Abstract][Full Text] [Related]
18. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
[TBL] [Abstract][Full Text] [Related]
19. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
20. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
